Blastic Plasmacytoid Dendritic Cell Neoplasm: Update on molecular biology, diagnosis, and therapy

Cancer Control

Volumn 21, Issue 4, 2014, Pages 279-289

  Riaz, Wasif ^a   Zhang, Ling ^b   Horna, Pedro ^b   Sokol, Lubomir ^c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b Departments of Hematopathology and Laboratory Medicine   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ASPARAGINASE; AZACITIDINE; CD123 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; METHOTREXATE; PRALATREXATE; PREDNISONE; RECOMBINANT INTERLEUKIN 3; SL 401; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM; CANCER PROGNOSIS; CHILL; CHROMOSOME ABERRATION; CONSOLIDATION CHEMOTHERAPY; CYTOLOGY; DIFFERENTIAL DIAGNOSIS; DISEASE FREE SURVIVAL; DRUG MEGADOSE; EPSTEIN BARR VIRUS; EVENT FREE SURVIVAL; FEVER; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; HYPOTENSION; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; MAINTENANCE THERAPY; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL EDEMA; PLASMACYTOID DENDRITIC CELL; PROGRESSION FREE SURVIVAL; SKIN BIOPSY; SURVIVAL RATE; THROMBOCYTOPENIA; DENDRITIC CELL; HEMATOLOGIC NEOPLASMS; MORTALITY; PATHOLOGY;

DENDRITIC CELLS; HEMATOLOGIC NEOPLASMS; HUMANS;

EID: 84907819283     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481402100404     Document Type: Article

References (71)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
2. Adachi M, Maeda K, Takekawa M, et al. High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma. Am J Hematol. 1994;47(4):278-282.
3. Brody JP, Allen S, Schulman P, et al. Acute agranular CD4-positive natural killer cell leukemia. Comprehensive clinicopathologic studies including virologic and in vitro culture with inducing agents. Cancer 1995;75(10):2474-2483.
4. DiGiuseppe JA, Louie DC, Williams JE, et al. Blastic natural killer cell leukemia/lymphoma: a clinicopathologic study. Am J Surg Pathol. 1997;21(10):1223-1230.
5. Petrella T, Comeau MR, Maynadié M, et al. ‘Agranular CD4+ CD56+ hematodermic neoplasm’ (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol. 2002;26(7):852-862.
6. Jaffe ES, Stein H, et al. Pathology and Genetics. Tumours of the Haematopoietic and Lymphoid Tissues. 3rd ed. Lyon, France: IARC Press; 2001.
7. Julia F, Dalle S, Duru G, et al. Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients. Am J Surg Pathol. 2014;38(5):673-680.
8. Pagano L, Valentini CG, Pulsoni A, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98(2):239-246.
9. Bueno C, Almeida J, Lucio P, et al. Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. Haematologica. 2004;89(1):58-69.
10. Ng AP, Lade S, Rutherford T, et al. Primary cutaneous CD4+/CD56+ hematodermic neoplasm (blastic NK-cell lymphoma): a report of five cases. Haematologica. 2006;91(1):143-144.
11. Jacob MC, Chaperot L, Mossuz P, et al. CD4+ CD56+ lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells. Haematologica. 2003;88(8): 941-955.
12. Oshimi K, Kawa K, Nakamura S, et al. NK-cell neoplasms in Japan. Hematology. 2005;10(3):237-245.
13. Petrella T, Bagot M, Willemze R, et al. Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol. 2005;123(5):662-675.
14. Uchida Y, Kawai K, Kubo H, et al. Blastic plasmacytoid dendritic cell neoplasm in a human T-cell lymphotropic virus type I (HTLV-1) carrier: a coincidental association? Eur J Dermatol. 2013;23(2):250-251.
15. Khoury JD, Medeiros LJ, Manning JT, et al. CD56(+) TdT(+) blastic natural killer cell tumor of the skin: a primitive systemic malignancy related to myelomonocytic leukemia. Cancer. 2002;94(9):2401-2408.
16. Li HS, Watowich SS. Diversification of dendritic cell subsets: emerging roles of STAT proteins. JAKSTAT. 2013;2(4):e25112.
17. Chaperot L, Bendriss N, Manches O, et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood. 2001;97(10):3210-3217.
18. Tversky JR, Le TV, Bieneman AP, et al. Human blood dendritic cells from allergic subjects have impaired capacity to produce interferon-alpha via Toll-like receptor 9. Clin Exp Allergy. 2008;38(5):781-788.
19. Jegalian AG, Facchetti F, Jaffe ES. Plasmacytoid dendritic cells: physiologic roles and pathologic states. Adv Anat Pathol. 2009;16(6):392-404.
20. Vermi W, Facchetti F, Rosati S et al. Nodal and extranodal tumor-forming accumulation of plasmacytoid monocytes/interferon-producing cells associated with myeloid disorders. Am J Surg Pathol. 2004;28(5):585-595.
21. Reizis B, Bunin A, Ghosh HS, et al. Plasmacytoid dendritic cells: recent progress and open questions. Annu Rev Immunol. 2011;29:163-183.
22. MacDonald KP, Munster DJ, Clark GJ, et al. Characterization of human blood dendritic cell subsets. Blood. 2002;100(13):4512-4520.
23. Osaki Y, Yokohama A, Saito A, et al. Characterization of CD56+ dendritic-like cells: a normal counterpart of blastic plasmacytoid dendritic cell neoplasm? PLoS One. 2013;8(11):e81722.
24. Leroux D, Mugneret F, Callanan M, et al. CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Français de Cytogénétique Hématologique. Blood. 2002;99(11):4154-4159.
25. Lucioni M, Novara F, Fiandrino G, et al. Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion. Blood. 2011;118(17):4591-4594.
26. Wiesner T, Obenauf AC, Cota C, et al. Alterations of the cell-cycle inhibitors p27(KIP1) and p16(INK4a) are frequent in blastic plasmacytoid dendritic cell neoplasms. J Invest Dermatol. 2010;130(4):1152-1157.
27. Tokuda K, Eguchi-Ishimae M, Yagi C, et al. CLTC-ALK fusion as a primary event in congenital blastic plasmacytoid dendritic cell neoplasm. Genes Chromosomes Cancer. 2014;53(1):78-89.
28. Sapienza MR, Fuligni F, Agostinelli C, et al. Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-KB pathway inhibition. Leukemia. 2014;28(8):1606-1616.
29. Dijkman R, van Doorn R, Szuhai K, et al. Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood. 2007;109(4):1720-1727.
30. Alayed K, Patel KP, Konoplev S, et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013;88(12):1055-1061.
31. Menezes J, Acquadro F, Wiseman M, et al. Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2014;28(4):823-829.
32. Taylor J, Kim SS, Stevenson KE, et al. Loss-of-function mutations in the splicing factor ZRSR2 are common in blastic plasmacytoid dendritic cell neoplasm and have male predominance. Blood. 2013;122(21):741.
33. Sugimoto KJ, Shimada A, Yamaguchi N, et al. Sustained complete remission of a limited-stage blastic plasmacytoid dendritic cell neoplasm followed by a simultaneous combination of low-dose DeVIC therapy and radiation therapy: a case report and review of the literature. Int J Clin Exp Pathol. 2013;6(11):2603-2608.
34. Li Y, Li Z, Lin HL, et al. Primary cutaneous blastic plasmacytoid dendritic cell neoplasm without extracutaneous manifestation: case report and review of the literature. Pathol Res Pract. 2011;207(1):55-59.
35. Pileri A, Delfino C, Grandi V, et al. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): the cutaneous sanctuary. G Ital Dermatol Venereol. 2012;147(6):603-608
36. Rauh MJ, Rahman F, Good D, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation, lacking cutaneous involvement: case series and literature review. Leuk Res. 2012;36(1):81-86.
37. Herling M, Teitell MA, Shen RR, et al. TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. Blood. 2003;101(12):5007-5009.
38. Petrella T, Meijer CJ, Dalac S, et al. TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis. Am J Clin Pathol. 2004;122(2):307-313.
39. Pilichowska ME, Fleming MD, Pinkus JL, et al. CD4+/CD56+ hematodermic neoplasm (“blastic natural killer cell lymphoma”): neoplastic cells express the immature dendritic cell marker BDCA2 and produce interferon. Am J Clin Pathol. 2007;128(3):445-453.
40. Reichard KK, Burks EJ, Foucar MK, et al. CD4(+) CD56(+) lineage-negative malignancies are rare tumors of plasmacytoid dendritic cells. Am J Surg Pathol. 2005;29(10):1274-1283.
41. Marafioti T, Paterson JC, Ballabio E, et al. Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood. 2008;111(7):3778-3792.
42. Montes-Moreno S, Ramos-Medina R, Martínez-López A, et al. SPIB, a novel immunohistochemical marker for human blastic plasmacytoid dendritic cell neoplasms: characterization of its expression in major hematolymphoid neoplasms. Blood. 2013;121(4):643-647.
43. Salva KA, Haemel AK, Pincus LB, et al. Expression of CD31/PECAM-1 (platelet endothelial cell adhesion molecule 1) by blastic plasmacytoid dendritic cell neoplasms. JAMA Dermatol. 2014;150(1):73-76.
44. Garnache-Ottou F, Feuillard J, Ferrand C, et al. Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol. 2009;145(5):624-636.
45. Sangle NA, Schmidt RL, Patel JL, et al. Optimized immunohistochemical panel to differentiate myeloid sarcoma from blastic plasmacytoid dendritic cell neoplasm. Mod Pathol. 2014;27(8):1137-1143.
46. Song SX, Willemze R, Swerdlow SH, et al. Mycosis fungoides: report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop. Am J Clin Pathol. 2013;139(4):466-490.
47. Liang X, Graham DK. Natural killer cell neoplasms. Cancer. 2008;112(7):1425-1436.
48. Vitte F, Fabiani B, Bénet C, et al. Specific skin lesions in chronic myelomonocytic leukemia: a spectrum of myelomonocytic and dendritic cell proliferations: a study of 42 cases. Am J Surg Pathol. 2012;36(9):1302-1316.
49. Assaf C, Gellrich S, Whittaker S, et al. CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer. J Clin Pathol. 2007;60(9):981-989.
50. Piccaluga PP, Paolini S, Sapienza MR, et al. Blastic plasmacytoid dendritic cell neoplasm: is it time to redefine the standard of care? Expert Rev Hematol. 2012;5(4):353-355.
51. Feuillard J, Jacob MC, Valensi F, et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood. 2002;99(5):1556-1563.
52. Pemmaraju N, Deborah A. Kantarijan H, et al. Analysis of outcomes of patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN) [Abstract]. J Clin Oncol. 2010;30(suppl):6578.
53. Dietrich S, Andrulis M, Hegenbart U, et al. Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients: results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity. Biol Blood Marrow Transplant. 2011;17(8):1250-1254.
54. An HJ, Yoon DH, Kim S, et al. Blastic plasmacytoid dendritic cell neoplasm: a single-center experience. Ann Hematol. 2013;92(3):351-356.
55. Gills L, Lebras L, Bouafia-Sauvy F, et al. Sequential combination of high dose methotrexate and L-asparaginase followed by allogeneic transplant: a first-line strategy for CD4+/CD56+ hematodermic neoplasm. Leuk Lymphoma. 2012;53(8):1633-1637.
56. Gruson B, Vaida I, Merlusca L, et al. L-asparaginase with methotrexate and dexamethasone is an effective treatment combination in blastic plasmacytoid dendritic cell neoplasm. Br J Haematol. 2013;163(4):543-545.
57. Leitenberger JJ, Berthelot CN, Polder KD, et al. CD4+ CD56+ hematodermic/ plasmacytoid dendritic cell tumor with response to pralatrexate. J Am Acad Dermatol. 2008;58(3):480-484.
58. Hatano Y, Ogata M, Ohishi M, et al. Maintenance of long-term remission using oral administration of low-dose etoposide in a patient demonstrating a relapse of blastic natural killer-cell lymphoma. Clin Exp Dermatol. 2007;32(1):96-97.
59. Dalle S, Beylot-Barry M, Bagot M, et al. Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol. 2010;162(1):74-79.
60. Kharfan-Dabaja MA, Lazarus HM, Nishihori T, et al. Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19(7):1006-1012.
61. Suzuki R, Suzumiya J, Nakamura S, et al. Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transplant. 2006;37(4):425-431.
62. Reimer P, Rüdiger T, Kraemer D, et al. What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant. 2003;32(7):637-646.
63. Roos-Weil D, Dietrich S, Boumendil A, et al. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2013;121(3):440-446.
64. Pemmaraju N, Thomas D, Kantarjian HM, et al. Analysis of outcomes of patients with blastic plasmacytoid dendritic cell neoplasm. https://ash.confex.com/ash/2012/webprogram/Paper53971.html. Accessed July 28, 2014.
65. Unteregger M, Valentin A, Zinke-Cerwenka W, et al. Unrelated SCT induces long-term remission in patients with blastic plasmacytoid dendritic cell neoplasm. Bone Marrow Transplant. 2013;48(6):799-802.
66. Jegalian AG, Buxbaum NP, Facchetti F, et al. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica. 2010;95(11):1873-1879.
67. Agliano A, Martin-Padura I, Marighetti P, et al. Therapeutic effect of lenalidomide in a novel xenograft mouse model of human blastic NK cell lymphoma/blastic plasmacytoid dendritic cell neoplasm. Clin Cancer Res. 2011;17(19):6163-6173.
68. Laribi K, Denizon N, Ghnaya H, et al. Blastic plasmacytoid dendritic cell neoplasm: the first report of 2 cases treated by 5-azacytidine. Eur J Haematol. 2014;93(1):81-85.
69. Frankel AE, McCubrey JA, Miller MS, et al. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. Leukemia. 2000;14(4):576-585.
70. Angelot-Delettre F, Frankel AE, Liu JS, et al. The IL-3Ra-targeted drug SL-401 selectively kills blastic plasmacytoid dendritic cell neoplasm cells. https://ash.confex.com/ash/2011/webprogram/Paper37851.html. Accessed July 28, 2014.
71. Frankel AE, Woo JH, Ahn C, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124(3):385-392.